C4 Therapeutics, Inc. (CCCC) Institutional Ownership

Ownership Summary

C4 Therapeutics, Inc. (NASDAQ:CCCC) currently has 2 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in C4 Therapeutics edged down to 0.3% in December 2025, compared to 72.0% in September 2025.
• The company experienced a 15.65% quarterly change in institutional shares held, alongside a decrease of 98.25% in total owners annually.
• The latest 13F cycle for C4 Therapeutics reveals that of 2 total investors, 1 funds grew their exposure, whereas 0 reduced theirs and 1 made no changes.
• The total number of shares held by institutions in C4 Therapeutics increased to 237.29K as of December 2025, a net change of up by 32.10K shares quarter on quarter, and down 64.24Mn shares year over year.
• With 237.14K shares, Hennion & Walsh Asset Management, Inc. commands the largest institutional position in C4 Therapeutics as of December 31, 2025, equating to 0.32% of the company.
• Among the most significant buyers of C4 Therapeutics during December 2025 were Hennion & Walsh Asset Management, Inc. (32.10K).
• The top 2 institutional holders of C4 Therapeutics for the quarter ending December 2025 included Hennion & Walsh Asset Management, Inc. (237.14K), NISA INVESTMENT ADVISORS, LLC (156).